PRESS RELEASE published on 05/26/2026 at 19:00, 2 months 21 days ago Inside Information / Other news releases MaaT Pharma provides a business update and reports financial results for the first quarter of 2026, highlighting regulatory activities and cash position. Lyon, France Financial Results Business Update Cash Position MaaT Pharma Regulatory Activities
BRIEF published on 05/20/2026 at 20:50, 2 months 27 days ago MAAT Pharma Faces Setback in Authorization for MaaT013 Biotech MaaT Pharma EMA MaaT013 AGvHD
PRESS RELEASE published on 05/20/2026 at 20:45, 2 months 27 days ago Inside Information / Other news releases MaaT Pharma receives a 'negative trend' opinion from CHMP for their Marketing Authorization Application of MaaT013 (Xervyteg) in acute Graft-versus-Host Disease treatment. Company plans re-examination procedure MaaT Pharma CHMP Marketing Authorization Negative Trend Re-examination
BRIEF published on 04/21/2026 at 15:14, 3 months 25 days ago MaaT Pharma SACA Maintains Buy Rating with Stable Financial Outlook Financial Performance BUY Rating Pipeline Development MaaT Pharma Investment Case
PRESS RELEASE published on 04/21/2026 at 15:09, 3 months 25 days ago Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research reaffirms Buy rating for MaaT Pharma SACA with a target price of €17 following FY25 results and pipeline update. No changes to core investment case First Berlin Equity Research BUY Rating MaaT Pharma SACA FY25 Results €17 Target Price
BRIEF published on 04/01/2026 at 07:35, 4 months 15 days ago MaaT Pharma publishes data on aGvH in "Bone Marrow Transplantation" MaaT Pharma EMA AGvH Xervyteg® CHRONOS
BRIEF published on 04/01/2026 at 07:35, 4 months 15 days ago MaaT Pharma Presents CHRONOS Study Results on Third-Line Acute GvHD MaaT Pharma Regulatory Review CHRONOS Study Acute GvHD Third-line Therapy
PRESS RELEASE published on 04/01/2026 at 07:30, 4 months 15 days ago Inside Information / Other news releases MaaT Pharma announces publication of retrospective data from CHRONOS study in Bone Marrow Transplantation Journal, presenting real-world outcomes of third-line systemic treatments for GI-aGvHD patients MaaT Pharma GI-aGvHD CHRONOS Study Retrospective Data Bone Marrow Transplantation
BRIEF published on 03/31/2026 at 07:35, 4 months 16 days ago MaaT Pharma: 2025 Revenue and Clinical Progress Revenue Funding Clinical Development MaaT Pharma Microbiothérapies
BRIEF published on 01/20/2026 at 18:35, 6 months 27 days ago MaaT Pharma Launches Phase 2 Trial for NSCLC Patients NSCLC MaaT Pharma Gut Microbiome IMMUNOLIFE Phase 2 Antibiotic-induced Dysbiosis
Published on 08/15/2026 at 00:15, 2 days ago Full Circle Lithium Announces Closing of Private Placement
Published on 08/14/2026 at 23:45, 2 days 1 hour ago AI/ML Innovations Inc. Announces Proposed Private Placement
Published on 08/14/2026 at 23:00, 2 days 1 hour ago Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call
Published on 08/16/2026 at 19:40, 5 hours 15 minutes ago APIC delivers 55% EBITDA growth in the first half of 2026, reaching USD 44 million
Published on 08/16/2026 at 13:40, 11 hours 15 minutes ago Ajax says goodbye to Godts with a classy message in Paris: THE FUTURE BELONGS TO YOUNG GODTS
Published on 08/16/2026 at 09:45, 15 hours 10 minutes ago Ragnarok Zero: Global Set to Officially Launch on August 18
Published on 08/16/2026 at 06:15, 18 hours 40 minutes ago Garvee Spotlights Home & Garden Essentials for the Late-Summer to Early-Autumn Transition
Published on 08/15/2026 at 15:05, 1 day 9 hours ago Brook Gaming Officially Launches Sniper 2 Flagship Keyboard and Mouse Converter for Cross-Platform Console Gaming
Published on 08/10/2026 at 18:00, 6 days 6 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 11:53, 6 days 13 hours ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
Published on 08/10/2026 at 11:36, 6 days 13 hours ago GUILLEMOT CORPORATION| Weekly report share buyback from August 3 to August 7 2026
Published on 08/10/2026 at 09:22, 6 days 15 hours ago Number of shares and voting rights - July 2026 (In French only)
